NO20034204L - Farmasöytiske kombinasjoner til behandling av kreft - Google Patents

Farmasöytiske kombinasjoner til behandling av kreft

Info

Publication number
NO20034204L
NO20034204L NO20034204A NO20034204A NO20034204L NO 20034204 L NO20034204 L NO 20034204L NO 20034204 A NO20034204 A NO 20034204A NO 20034204 A NO20034204 A NO 20034204A NO 20034204 L NO20034204 L NO 20034204L
Authority
NO
Norway
Prior art keywords
cancer
treatment
pharmaceutical combinations
formula
therapeutic agent
Prior art date
Application number
NO20034204A
Other languages
English (en)
Norwegian (no)
Other versions
NO20034204D0 (no
Inventor
Francis J Giles
Hagop M Kantarjian
Jacques Jolivet
Original Assignee
Shire Biochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Biochem Inc filed Critical Shire Biochem Inc
Publication of NO20034204D0 publication Critical patent/NO20034204D0/no
Publication of NO20034204L publication Critical patent/NO20034204L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
NO20034204A 2001-03-23 2003-09-22 Farmasöytiske kombinasjoner til behandling av kreft NO20034204L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27797501P 2001-03-23 2001-03-23
US33060101P 2001-10-25 2001-10-25
PCT/CA2002/000426 WO2002076472A2 (fr) 2001-03-23 2002-03-25 Combinaisons pharmaceutiques destinees au traitement du cancer

Publications (2)

Publication Number Publication Date
NO20034204D0 NO20034204D0 (no) 2003-09-22
NO20034204L true NO20034204L (no) 2003-11-21

Family

ID=26958821

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034204A NO20034204L (no) 2001-03-23 2003-09-22 Farmasöytiske kombinasjoner til behandling av kreft

Country Status (13)

Country Link
US (2) US6800639B2 (fr)
EP (1) EP1370270B1 (fr)
JP (1) JP4391087B2 (fr)
KR (1) KR20040018341A (fr)
AT (1) ATE450265T1 (fr)
CA (1) CA2441568A1 (fr)
DE (1) DE60234577D1 (fr)
HU (1) HUP0400314A3 (fr)
MX (1) MXPA03008623A (fr)
NO (1) NO20034204L (fr)
NZ (1) NZ528394A (fr)
PL (1) PL365285A1 (fr)
WO (1) WO2002076472A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2383259A1 (fr) 2002-04-23 2003-10-23 Celator Technologies Inc. Composes synergiques
US8383605B2 (en) * 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
JP2005535688A (ja) * 2002-07-30 2005-11-24 ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗腫瘍医薬との組合せにおけるアルキルホスホコリンの使用
US20040192652A1 (en) * 2002-12-06 2004-09-30 Giles Francis J. Pharmaceutical combinations and methods for the treatment of leukemia
JP2006525236A (ja) * 2003-04-02 2006-11-09 セレーター ファーマスーティカルズ、インク． 薬剤耐性の治療組成物
CA2811272C (fr) 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Formulations pharmaceutiques contenant de la methylnaltrexone
US20040248915A1 (en) * 2003-04-25 2004-12-09 Jacques Jolivet Method for administration of troxacitabine
ES2425083T3 (es) * 2003-09-25 2013-10-11 Astellas Pharma Inc. Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
JP2009507918A (ja) 2005-09-12 2009-02-26 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション Ｂｃｌ２関連癌の診断及び療法のための組成物及び方法
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
KR20090057050A (ko) * 2006-09-01 2009-06-03 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 암치료를 위한 트록사시타빈 전구약물
JP2010522756A (ja) 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
PL2137191T3 (pl) 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
EP2565195B1 (fr) 2007-03-29 2015-05-06 Wyeth LLC Récepteur opioïde périphérique et son antagoniste ainsi que leurs utilisations
WO2009023845A2 (fr) * 2007-08-15 2009-02-19 The Board Of Regents Of The University Of Texas System Thérapie combinatoire avec triterpénoïdes synthétiques et gemcitabine
BRPI0907423A2 (pt) 2008-01-11 2020-10-27 Reata Pharmaceuticals, Inc. composto triterpenoide sintético para uso em um método de melhoria da função renal em um indivíduo, e uso do referido composto
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
CA2719134C (fr) 2008-03-21 2015-06-30 The University Of Chicago Traitement avec des antagonistes des opioides et des inhibiteurs mtor
US20100004193A1 (en) * 2008-07-07 2010-01-07 Fondazione Per La Ricerca Biomedica Avanzata Onlus - Istituto Veneto Di Medicina Molecolare Combination therapy
CA2676881C (fr) 2008-09-30 2017-04-25 Wyeth Antagonistes de recepteurs opioides peripheriques, et leurs utilisations
WO2011123691A1 (fr) 2010-03-31 2011-10-06 Keryx Biopharmaceuticals, Inc. Périfosine et capécitabine en tant que traitement combiné du cancer
DK2558105T3 (da) 2010-04-12 2020-01-27 Reata Pharmaceuticals Inc Bardoxolonmethyl til behandling af fedme
US10613087B2 (en) * 2012-08-10 2020-04-07 Analiza, Inc. Methods and devices for analyzing species to determine diseases
JP7337539B2 (ja) 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
CN118511077A (zh) 2021-10-28 2024-08-16 克利夫兰诊断有限公司 用于确定多种类型的癌症的分配系统和方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350753B1 (en) 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US5041449A (en) 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5270315A (en) 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US5817667A (en) 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
WO1992018517A1 (fr) * 1991-04-17 1992-10-29 Yale University Procede de traitement ou de prevention du virus de l'hepatite b
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
WO2000057861A2 (fr) * 1999-03-29 2000-10-05 Shire Biochem Inc. Techniques de traitement de la leucemie
AU2002212015B2 (en) 2000-10-13 2007-01-25 Shire Canada Inc. Dioxolane analogs for improved inter-cellular delivery
US20040248915A1 (en) * 2003-04-25 2004-12-09 Jacques Jolivet Method for administration of troxacitabine

Also Published As

Publication number Publication date
WO2002076472A3 (fr) 2003-04-10
NZ528394A (en) 2005-06-24
JP2004525142A (ja) 2004-08-19
CA2441568A1 (fr) 2002-10-03
KR20040018341A (ko) 2004-03-03
HUP0400314A3 (en) 2006-02-28
EP1370270A2 (fr) 2003-12-17
JP4391087B2 (ja) 2009-12-24
US6800639B2 (en) 2004-10-05
PL365285A1 (en) 2004-12-27
US20050004081A1 (en) 2005-01-06
WO2002076472A2 (fr) 2002-10-03
NO20034204D0 (no) 2003-09-22
MXPA03008623A (es) 2004-05-21
ATE450265T1 (de) 2009-12-15
US20030083316A1 (en) 2003-05-01
HUP0400314A2 (hu) 2004-08-30
DE60234577D1 (de) 2010-01-14
EP1370270B1 (fr) 2009-12-02

Similar Documents

Publication Publication Date Title
NO20034204L (no) Farmasöytiske kombinasjoner til behandling av kreft
AP1782A (en) Use of compounds ?-D or ?-L nucleoside for treating hepatitis C virus.
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
MXPA04012965A (es) Inhibidores virales.
BR0012450A (pt) Benzimidazóis substituìdos
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
MY151199A (en) Substituted diphenyl heterocycles useful for treating hcv infection
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
ATE512976T1 (de) Hemmer des hepatitis-c-virus
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
ATE232862T1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
PT1200412E (pt) Agentes anti-proliferativos de imidazole
NO20024005D0 (no) Pteridinforbindelser for behandling av psoriasis
DE50310516D1 (de) Fredericamycin-derivate
BRPI0515896A (pt) composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
SE0101932D0 (sv) Pharmaceutical combinations
EA200200922A1 (ru) Композиция, включающая камптотецин и производное пиримидина, для лечения рака
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
WO2002094796A3 (fr) Derives de la benzo[g]quinoxaline composes efficaces contre les maladies infectieuses
IL165259A (en) Compounds useful in the treatment of anthrax and inhibiting lethal factor
MXPA04005809A (es) Inhibidores de proteinas quinasas.
DE60128100D1 (de) Analgetisches arzneimittel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application